Vue normale Vue MARC vue ISBD

First-line management of advanced or metastatic clear cell renal cancer: How long should immunotherapy and/or anti-angiogenic therapy last? What are the criteria for stopping or continuing treatment?

Borchiellini, Delphine

First-line management of advanced or metastatic clear cell renal cancer: How long should immunotherapy and/or anti-angiogenic therapy last? What are the criteria for stopping or continuing treatment? - 2024.

19

Imprimer
Ajouter à mon panier (Supprimer)
Rapporter un problème
Enregistrer la notice
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
Plus de recherches

Chercher ce titre dans :
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

First-line management of advanced or metastatic clear cell renal cancer: How long should immunotherapy and/or anti-angiogenic therapy last? What are the criteria for stopping or continuing treatment?

PLUDOC

Adresse

Liens utiles

First-line management of advanced or metastatic clear cell renal cancer: How long should immunotherapy and/or anti-angiogenic therapy last? What are the criteria for stopping or continuing treatment?

PLUDOC

Adresse

Réseaux sociaux

Liens utiles